SHARE

GSK acquires US oncology biotech Nuvalent for $10.6bn in largest deal in over a decade

GSK’s $10.6bn acquisition of Nuvalent marks its biggest deal since 2012 and the first under new CEO Luke Miels. Nuvalent specialises in targeted lung cancer therapies, expanding GSK’s oncology pipeline.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.